SCHEMBL21889972

SCHEMBL21889972

C#CCNC(=O)C(=O)c1c(C)c(C(=O)Nc2ccc(F)c(C#N)c2)n2c1CCC2

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SLC10A1 Q14973 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22511164 0.91 SLC10A1 (0.58) SLC10A1
SCHEMBL21890573 0.91 SLC10A1 (0.69) SLC10A1
SCHEMBL22511167 0.89 SLC10A1 (0.68) SLC10A1
SCHEMBL21889975 0.88 SLC10A1 (0.61) SLC10A1
SCHEMBL21889971 0.87 SLC10A1 (0.66) SLC10A1
SCHEMBL21890556 0.86 SLC10A1 (0.65) SLC10A1
SCHEMBL21889978 0.86 SLC10A1 (0.65) SLC10A1
SCHEMBL21890557 0.84 SLC10A1 (0.73) SLC10A1
SCHEMBL22528159 0.84 SLC10A1 (0.78) SLC10A1
SCHEMBL22545559 0.84 SLC10A1 (0.78) SLC10A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4733305-A2 PYRROLE COMPOUNDS Aligos Therapeutics, Inc. (US) 2026-04-29 EP disclosed
US-12599582-B2 Pyrrole compounds ALIGOS THERAPEUTICS, INC. (US) 2026-04-14 US disclosed
EP-3947349-B1 PYRROLE COMPOUNDS ALIGOS THERAPEUTICS INC (US) 2026-03-11 EP disclosed
US-20230390242-A1 PYRROLE COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-12-07 US disclosed
US-11771680-B2 Pyrrole compounds ALIGOS THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-11771680-B2 Pyrrole compounds ALIGOS THERAPEUTICS, INC. (US) 2023-10-03 US disclosed
US-20230056135-A1 MONOMER AND MULTIMERIC ANTI-HBV AGENTS EMORY UNIVERSITY (US) 2023-02-23 US disclosed
US-20220071957-A1 PYRROLE COMPOUNDS EMORY UNIVERSITY 2022-03-10 US disclosed
US-11191747-B2 Pyrrole compounds ALIGOS THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-11191747-B2 Pyrrole compounds ALIGOS THERAPEUTICS, INC. (US) 2021-12-07 US disclosed
US-20200323821-A1 PYRROLE COMPOUNDS EMORY UNIVERSITY 2020-10-15 US disclosed
US-20200323821-A1 PYRROLE COMPOUNDS EMORY UNIVERSITY 2020-10-15 US disclosed
WO-2020205934-A1 PYRROLE COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed
WO-2020072955-A1 MONOMER AND MULTIMERIC ANTI-HBV AGENTS EMORY UNIVERSITY (US) 2020-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390242-A1 PYRROLE COMPOUNDS PKD1, ADCYAP1R1, PYCR1 SLC10A1 48/4885
US-12599582-B2 Pyrrole compounds PEF1, CYP4F8, CYP2C19 SLC10A1 74/4885
US-20230056135-A1 MONOMER AND MULTIMERIC ANTI-HBV AGENTS HAVCR2, HMBS, HDGF SLC10A1 8/4885
US-11771680-B2 Pyrrole compounds PKD1, ADCYAP1R1, PYCR1 SLC10A1 48/4885
US-20200323821-A1 PYRROLE COMPOUNDS PKD1, ADCYAP1R1, PYCR1 SLC10A1 48/4885
US-20220071957-A1 PYRROLE COMPOUNDS PKD1, ADCYAP1R1, PYCR1 SLC10A1 48/4885
US-11191747-B2 Pyrrole compounds PKD1, ADCYAP1R1, PYCR1 SLC10A1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.